Each year, there are approximately 50 million Dengue infections and an estimated 500,000 individuals are hospitalized with Dengue haemorrhagic fever. There have been attempts to develop a Dengue vaccine since the 1940s, but due to the limited appreciation of its global disease burden and market value, the industry’s interest deteriorated in the 20th century.
In 2013, the WHO ranked Dengue as the fastest spreading vector-borne viral disease, with an epidemic potential in the world. According to the WHO, any vaccine developed must also be incorporated into current prevention methods. Therefore, Dengue vaccines will complement, but not replace vector control, already in place.
There has been an explosive increase in Dengue cases in recent years and in response, the development of Dengue vaccines has accelerated significantly. Currently there are several vaccines in clinical trials. These include, Sanofi Pasteur (Phase III), Inviragen (now part of Takeda in Phase II), NIH with Butantan Institute (Phase II), Merck (Phase I), GlaxoSmithKline in collaboration with Oswaldo Cruz Foundation and Walter Reed Army Institute of Research (Phase I) and the Naval Medical Research Center with Walter Reed Army Institute of Research in Phase I.
Sanofi Pasteur’s Dengue vaccine is the most far ahead. In September last year, Sanofi Pasteur announced that their vaccine successfully completed its final Phase III clinical efficacy study in Latin America. With an overall vaccine efficacy of 60.8 percent and illustrated efficacy against each of the four Dengue serotypes, the results also showed a significant reduction of the risk of hospitalization by 80.3 percent confirming the potential public health impact of the vaccine.
Dr Guillaume Leroy, Vice President Dengue Vaccine at Sanofi Pasteur leads the Dengue team and is currently focusing on an equitable access approach to the vaccine by working with an extensive network of external collaborations. With partners, Dr Leroy is consolidating all activities and resources towards a common goal of making Dengue the next vaccine-preventable disease.
Dr Leroy is the best representative to illustrate Sanofi’s vision and engagement plan for successfully executing the vaccine to Dengue-stricken areas. Speaking at the Emerging and Re-emerging Diseases Conference (as part of the 15th World Vaccine Congress taking place on April 7 – 9, Washington DC), Dr Leroy will cover Sanofi’s rationale for delving into the emerging diseases market in addressing the Dengue burden to have a public health impact, sharing Phase III efficacy results and clinical platform as well as exploring unique collaborations to successfully execute the vaccine. Meet Dr Leroy and find out more at World Vaccine Congress for more information.